Page 196 - rcv31n3.vp

Actualización en medicamentos antidiabéticos y riesgo cardiovascular Revista Uruguaya de Cardiología
María del Pilar Serra Sansone Volumen 31 | nº 3 | Diciembre 2016

48. Preiss D, Lloyd SM, Ford I, McMurray JJ, Hol- 60. Meinert CL, Knatterud GL, Prout TE, Klimt CR.
man RR, Welsh P, et al. Metformin for non-diabetic A study of the effects of hypoglycemic agents on vascu-
patients with coronary heart disease (the CAMERA lar complications in patients with adult-onset diabetes:
study): a randomised controlled trial. Lancet Diabetes mortality results. Diabetes 1970; 19(Suppl):789-830.
Endocrinol 2014; 2(2):116-24.
61. Monami M, Genovese S, Mannucci E. Cardiovas-
49. Lundby-Christensen L, Tarnow L, Boesgaard cular safety of sulfonylureas: a meta-analysis of rando-
TW, Lund SS, Wiinberg N, Perrild H, et al. Met- mized clinical trials. Diabetes Obes Metab 2013;
formin versus placebo in combination with insulin ana- 15(10):938-53.
logues in patients with type 2 diabetes mellitus-the
62. Morgan CL, Mukherjee J, Jenkins-Jones S, Hol-
randomised, blinded Copenhagen Insulin and Metfor-
den SE, Currie CJ. Association between first-line
min Therapy (CIMT) trial. BMJ Open 2016;
monotherapy with sulphonylurea versus metformin
6(2):e008376.
and risk of all-cause mortality and cardiovascular
50. United Sates. National Institute of Health. events: a retrospective, observational study. Diabetes
REducing With MetfOrmin Vascular Adverse Lesions Obes Metab 2014; 16(10):957-62.
in Type 1 Diabetes (REMOVAL). Washington, DC: 63. Johnsen SP,Monster TB,Olsen ML,Thisted H,
NIH, 2016. Disponible en: https://www.clinical- McLaughlin JK, Sørensen HT, et al. Risk and
trials.gov/ct2/show/NCT01483560. [Consulta: 20 julio short-term prognosis of myocardial infarction among
2016]. users of antidiabetic drugs. Am J Ther 2006;
13(2):134-40.
51. Maruthur NM, Tseng E, Hutfless S, Wilson LM,
Suarez-CuervoC,BergerZ,etal. Diabetes medica- 64. Simpson SH, Majumdar SR, Tsuyuki RT, Eurich
tionsasmonotherapyormetformin-basedcombination DT, Johnson JA. Dose-response relation between
therapy for Type 2 diabetes: a systematic review and sulfonylurea drugs and mortality in type 2 diabetes me-
meta-analysis.AnnInternMed2016;164(11):740-51. llitus: a population-based cohort study. CMAJ 2006;
174(2):169-74.
52. Natali A, Ferrannini E. Effects of metformin and
thiazolidinediones on suppression of hepatic glucose 65. Pantalone KM, Kattan MW, Yu C, Wells BJ, Arri-
production and stimulation of glucose uptake in type 2 gain S, Jain A, et al. The risk of overall mortality in
diabetes: a systematic review. Diabetologia 2006; patients with type 2 diabetes receiving glipizide, glybu-
49(3):434-41. ride, or glimepiride monotherapy: a retrospective
analysis. Diabetes Care 2010; 33(6):1224-9.
53. Ferrannini E. The target of metformin in type 2 dia-
betes. N Engl J Med 2014; 371(16):1547-8. 66. Monami M, Balzi D, Lamanna C, Barchielli A,
Masotti G, Buiatti E, et al. Are sulphonylureas all
54. Maedler K, Carr RD, Bosco D, Zuellig RA, Ber- the same? a cohort study on cardiovascular and can-
ney T, Donath MY. Sulfonylurea induced beta-cell cer-related mortality. Diabetes Metab Res Rev 2007;
apoptosis in cultured human islets. J Clin Endocrinol 23(6):479-84.
Metab 2005; 90(1):501-6.
67. Khalangot M, Tronko M, Kravchenko V, Kovtun
55. Donath MY, Ehses JA, Maedler K, Schumann V. Glibenclamide-related excess in total and cardiovas-
DM, Ellingsgaard H, Eppler E, et al. Mechanisms cular mortality risks: data from large Ukrainian obser-
of beta-cell death in type 2 diabetes. Diabetes 2005; vational cohort study. Diabetes Res Clin Pract 2009;
54(Suppl 2):S108-13. 86(3):247-53.
56. Takahashi A, Nagashima K, Hamasaki A, Kuwa- 68. SimpsonSH, LeeJ,ChoiS,VandermeerB,
mura N, Kawasaki Y, Ikeda H, et al. Sulfonylurea Abdelmoneim AS, Featherstone TR. Mortality
and glinide reduce insulin content, functional expres- risk among sulfonylureas: a systematic review and net-
sion of K(ATP) channels, and accelerate apoptotic work meta-analysis. Lancet Diabetes Endocrinol 2015;
beta-cell death in the chronic phase. Diabetes Res Clin 3(1):43-51.
Pract 2007; 77(3):343-50.
69. Action to Control Cardiovascular Risk in Diabe-
57. Del Prato S, Pulizzi N. The place of sulfonylureas in tes Study Group; Gerstein HC, Miller ME, Bying-
the therapy for type 2 diabetes mellitus. Metabolism ton RP, Goff DC Jr, Bigger JT, Buse JB, et al.
2006; 55(5 Suppl 1):S20-7. Effects of intensive glucose lowering in type 2 diabetes.
N Engl J Med 2008; 358(24):2545-59.
58. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia,
70. Lexis CP, van der Horst IC, Lipsic E, van der
diabetes, and cardiovascular events. Diabetes Care
Harst P, van der Horst-Schrivers AN, Wolffen-
2010; 33(6):1389-94.
buttel BH, et al; GIPS-III Investigators. Metfor-
59. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, min in non-diabetic patients presenting with ST eleva-
Heath CW Jr. Body-mass index and mortality in a tion myocardial infarction: rationale and design of the
prospective cohort of U.S. adults. N Engl J Med 1999; glycometabolic intervention as adjunct to primary per-
341(15):1097-105. cutaneous intervention in ST elevation myocardial in-
540